SLC5A2 and type 2 diabetes mellitus: Dapagliflozin improved microbial abundance and variety in mice with diabetes, while in control healthy mice, only a minor effect was observed, suggesting a potential beneficial effect of SGLT2 inhibitors on gut microbiota when associated with T2DM [45].